Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> DNA Damage/DNA Repair

DNA Damage/DNA Repair

Products for  DNA Damage/DNA Repair

  1. Cat.No. Product Name Information
  2. GC12822 BML-210(CAY10433)

    NphenylN'(2Aminophenyl)hexamethylenediamide, CAY10433

     BML-210(CAY10433) is a novel HDAC inhibitor, and its mechanism of action has not been characterized. BML-210(CAY10433) Chemical Structure
  3. GC11648 BML-277

    BML-277, C 3742, Checkpoint Kinase 2 Inhibitor II

     Chk2 inhibitor,potent and highly selective BML-277 Chemical Structure
  4. GC19076 BMS-3 BMS-3 is a potent LIMK inhibitor with IC50s of 5 nM and 6 nM for LIMK1 and LIMK2, respectively. BMS-3 Chemical Structure
  5. GC12865 BMS265246 CDK1/2 inhibitor,potent and selective BMS265246 Chemical Structure
  6. GC34498 Bobcat339 hydrochloride Bobcat339 hydrochloride is a potent and selective cytosine-based inhibitor of TET enzyme, with the IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 hydrochloride is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription. Bobcat339 hydrochloride Chemical Structure
  7. GC11040 Borrelidin

    NSC 216128, Treponemycin

     threonyl-tRNA synthetase (ThrRS) inhibitor Borrelidin Chemical Structure
  8. GC48365 Bottromycin A2 An antibiotic Bottromycin A2 Chemical Structure
  9. GC73205 Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (Formula V) is a agent-linker conjugate that composed of a potent topoisomerase I inhibitor and a linker to make antibody agent conjugate (ADC). Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT Chemical Structure
  10. GC35547 BR102375 BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC50 value of 0.28?μM and Amax ratio?of 98%. BR102375 Chemical Structure
  11. GC50140 BRACO 19 trihydrochloride BRACO 19 trihydrochloride is a potent telomerase/telomere inhibitor with an IC50 value of 115±18nM, which prevents telomerase capping and catalysis. BRACO 19 trihydrochloride Chemical Structure
  12. GC62128 Bractoppin Bractoppin is a tandem BRCT (tandem BRCT, BRCA1) delivered by human breast and ovarian cancer suppressor protein (BRCA1) tBRCT domain recognizes a drug-like inhibitor of phosphopeptide that selectively inhibits nanomolar activity of substrate binding in vitro with an IC50 of 0.074 µM. Bractoppin Chemical Structure
  13. GC32702 Branaplam (LMI070)

    Branaplam, NVS-SM1

     Branaplam (LMI070) (LMI070; NVS-SM1) is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam (LMI070) inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam (LMI070) elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model. Branaplam (LMI070) Chemical Structure
  14. GC64383 Branaplam hydrochloride

    LMI070 hydrochloride; NVS-SM1 hydrochloride

     Branaplam (LMI070; NVS-SM1) hydrochloride is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam hydrochloride inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam hydrochloride elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model. Branaplam hydrochloride Chemical Structure
  15. GC33223 BRCA1-IN-1 BRCA1-IN-1 is a novel small-molecule-like BRCA1 inhibitor with IC50 and Ki of 0.53 μM and 0.71 μM, respecrively. BRCA1-IN-1 Chemical Structure
  16. GC35550 BRCA1-IN-2 BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for BRCA1 with an IC50 of 0.31 μM and a Kd of 0.3 μM, which shows antitumor activities via the disruption of BRCA1 (BRCT)2/protein interactions. BRCA1-IN-2 Chemical Structure
  17. GC33331 BRD 4354 BRD 4354 is a moderately potent inhibitor of HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM, respectively. BRD 4354 Chemical Structure
  18. GC35551 BRD 4354 ditrifluoroacetate BRD 4354 (ditrifluoroacetate) is a moderately potent inhibitor of HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM, respectively. BRD 4354 ditrifluoroacetate Chemical Structure
  19. GC50452 BRD 6989 Cdk8 inhibitor; enhances IL-10 production BRD 6989 Chemical Structure
  20. GC38742 BRD-6929

    JQ12

     An HDAC1 and HDAC2 inhibitor BRD-6929 Chemical Structure
  21. GC64111 BRD0539 BRD0539 is a cell-permeable and non-toxic inhibitor of CRISPR-Cas9. BRD0539 Chemical Structure
  22. GC72945 BRD2492 BRD2492 (compound 6d) is a potent, selective HDAC1 and HDAC2 inhibitor with IC50s of 13.2 nM and 77.2 nM, respecrtively. BRD2492 Chemical Structure
  23. GC12484 BRD73954 potent and selective HDAC inhibitor BRD73954 Chemical Structure
  24. GC68804 BRD7586

    BRD7586 is a small molecule inhibitor of SpCas9's cellular permeability. It is the smallest known anti-CRISPR inhibitor.

     BRD7586 Chemical Structure
  25. GC17683 Brefeldin A

    Ascotoxin, BFA, Cyanein, Decumbin, Nectrolide, NSC 56310, NSC 89671, NSC 107456, NSC 244390, Synergisidin

     Brefeldin A (BFA) is a fungal macrocyclic lactone and a potent, reversible inhibitor of intracellular vesicle formation and protein trafficking between the endoplasmic reticulum (ER) and the Golgi apparatus. Brefeldin A Chemical Structure
  26. GC19083 Briciclib

    ON-014185

     Briciclib is a water soluble derivative of ON 013100, and has the potential in targeting eIF4E for solid cancers. Briciclib Chemical Structure
  27. GC42978 Bromamphenicol Bromamphenicol is a dibrominated derivative of the antibiotic chloramphenicol. Bromamphenicol Chemical Structure
  28. GC50217 BS 181 dihydrochloride Selective cdk7 inhibitor BS 181 dihydrochloride Chemical Structure
  29. GC12001 BS-181 A selective Cdk7 inhibitor BS-181 Chemical Structure
  30. GC13690 BS-181 HCl BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9. BS-181 HCl Chemical Structure
  31. GC65128 BSJ-03-123 BSJ-03-123 is a PROTAC connected by ligands for Cereblon and CDK as a potent and novel CDK6-selective small-molecule degrader. BSJ-03-123 Chemical Structure
  32. GC50615 BSJ-03-204 Selective Cdk4/6 degrader BSJ-03-204 Chemical Structure
  33. GC73053 BSJ-03-204 triTFA BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 triTFA Chemical Structure
  34. GC62263 BSJ-4-116 BSJ-4-116 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC50 of 6 nM. BSJ-4-116 downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation). BSJ-4-116 exhibits potent antiproliferative effects, alone and in combination with the poly(ADP-ribose) polymerase inhibitor Olaparib. BSJ-4-116 Chemical Structure
  35. GC62880 BTX161 BTX161, a Thalidomide analog, is a potent CKIα degrader. BTX161 mediates degradation of CKIα better than Lenalidomide in human AML cells and activates DNA damage response (DDR) and p53, while stabilizing the p53 antagonist MDM2. BTX161 Chemical Structure
  36. GC15410 Bufexamac COX inhibitor Bufexamac Chemical Structure
  37. GC13671 Busulfan

    Busulphan, Mielosan, Milecitan, Myeloleukon, Mylecytan, Myleran, NCI C01592, NSC 750

     DNA alkylating agent Busulfan Chemical Structure
  38. GC46962 Busulfan-d8

    Busulphan-d8, Mielosan-d8, Milecitan-d8, Myeloleukon-d8, Mylecytan-d8, Myleran-d8

     An internal standard for the quantification of busulfan Busulfan-d8 Chemical Structure
  39. GC64761 Butyric acid-13C1 Butyric acid-13C1 Chemical Structure
  40. GC62136 BVDV-IN-1 BVDV-IN-1 is a non-nucleoside inhibitor (NNI) of bovine viral diarrhea virus (BVDV), with an EC50 of 1.8 μM. BVDV-IN-1 Chemical Structure
  41. GC72796 BW 348U87

    348U87

     BW 348U87 is an inhibitor for ribonucleotide reductase, which exhibits synergistic effect with Acyclovir , potentiate the antiviral activity of Acyclovir against HSV in atmic nude mouse model. BW 348U87 Chemical Structure
  42. GC61735 Bz-rA Phosphoramidite Bz-rA Phosphoramidite is used for ribonucleotides modification. Bz-rA Phosphoramidite Chemical Structure
  43. GC66885 Bz-rC Phosphoramidite Bz-rC Phosphoramidite is a phosphinamide monomer that can be used in the preparation of oligonucleotides. Bz-rC Phosphoramidite Chemical Structure
  44. GC13892 C527 Inhibitor of USP1/USF1 complex C527 Chemical Structure
  45. GC43109 C8 D-threo Ceramide (d18:1/8:0)

    D-threo Cer(d18:1/8:0), D-threo Ceramide (d18:1/8:0), N-octanoyl-D-threo-Sphingosine

     C8 D-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. C8 D-threo Ceramide (d18:1/8:0) Chemical Structure
  46. GC43111 C8 L-threo Ceramide (d18:1/8:0)

    L-threo Cer(d18:1/8:0), L-threo Ceramide (d18:1/8:0), N-octanoyl-L-threo-Sphingosine

     C8 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. C8 L-threo Ceramide (d18:1/8:0) Chemical Structure
  47. GC30977 Ca2+ channel agonist 1 Ca2+ channel agonist 1 is an agonist of N-type Ca2+ channel and an inhibitor of Cdk2, with EC50s of 14.23 μM and 3.34 μM, respectively, and is used as a potential treatment for motor nerve terminal dysfunction. Ca2+ channel agonist 1 Chemical Structure
  48. GC15306 Calcium N5-methyltetrahydrofolate Calcium salt of levomefolic acid Calcium N5-methyltetrahydrofolate Chemical Structure
  49. GC19086 Calicheamicin Calicheamicin is a cytotoxic agent that causes double-strand DNA breaks. Calicheamicin Chemical Structure
  50. GC15439 Camptothecin

    MAGCPT, NSC 94600

     Camptothecin is a specific DNA topoisomerase I (Top1) inhibitor with an IC50 value of 679 nM. Camptothecin Chemical Structure
  51. GC60669 Camptothecin-20(S)-O-propionate

    Camptothecin-20-O-propionate

     Camptothecin-20(S)-O-propionate (CZ48), the C20-propionate ester of CPT, is a highly effective anticancer agent. Camptothecin-20(S)-O-propionate (CZ48) is a topoisomerase-Ι inhibitor. Camptothecin-20(S)-O-propionate Chemical Structure
  52. GC15866 Capecitabine

    Ro 091978

     DNA, RNA and protein synthesis inhibitor Capecitabine Chemical Structure
  53. GC49415 Capsorubin A carotenoid with diverse biological activities Capsorubin Chemical Structure
  54. GC38896 Caracemide Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide Chemical Structure
  55. GC11207 Carboplatin

    CBDCA, CDDCA, cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), NSC 201345, NSC 241240

     Carboplatin (NSC 241240) is a non-specific DNA cross-linking agent that inhibits DNA synthesis and transcription. Its main target is DNA rather than specific proteins . Carboplatin Chemical Structure
  56. GC49286 Carboplatin-d4

    CDDCA-d4, cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)-d4, CBDCA-d4

     An internal standard for the quantification of carboplatin Carboplatin-d4 Chemical Structure
  57. GC49147 Carboxyphosphamide

    CPCOOH, NSC 145124

     An inactive metabolite of cyclophosphamide Carboxyphosphamide Chemical Structure
  58. GC12748 Carmofur

    HCFU

     Cytostatic derivative of fluorouracilm,antineoplatic agent Carmofur Chemical Structure
  59. GC15793 Carmustine

    BCNU, bis-Chloroethylnitrosourea, NSC 409962

     cell-cycle phase nonspecific alkylating antineoplastic agent Carmustine Chemical Structure
  60. GC91899 Carmustine-d8

    BCNU-d8; bis-Chloroethylnitrosourea-d8

     Carmustine-d8 is intended for use as an internal standard for the quantification of carmustine by GC- or LC-MS. Carmustine-d8 Chemical Structure
  61. GC66033 Casein kinase 1δ-IN-1 Casein kinase 1δ-IN-1 (compound 822) is an inhibitor of casein kinase 1 delta (CK1δ), exhibits inhibition of greater than 5%. Casein kinase 1δ-IN-1 can be used for neurodegenerative disorders such as Alzheimer's disease research. Casein kinase 1δ-IN-1 Chemical Structure
  62. GC67775 Casein kinase 1δ-IN-3 Casein kinase 1δ-IN-3 Chemical Structure
  63. GC71277 Casein kinase 1δ-IN-6 Casein kinase 1δ-IN-6 is a potent and selective protein kinase CK-1δ inhibitor with an IC50 of 23 nM. Casein kinase 1δ-IN-6 Chemical Structure
  64. GC72207 Casein Kinase 2 Substrate Peptide Casein Kinase 2 Substrate Peptide is a common CK2 substrate peptide. Casein Kinase 2 Substrate Peptide Chemical Structure
  65. GC30276 Casein Kinase II Inhibitor IV

    Casein Kinase II Inhibitor IV is a potent, ATP-competitive of casein kinase II inhibitor with an IC50 of 9 nM.

     Casein Kinase II Inhibitor IV Chemical Structure
  66. GC34356 Casein Kinase II Inhibitor IV Hydrochloride Casein Kinase II Inhibitor IV Hydrochloride is a small-molecule inducer of epidermal keratinocytedifferentiation. Casein Kinase II Inhibitor IV Hydrochloride Chemical Structure
  67. GC62442 Casein Kinase inhibitor A51 Casein Kinase inhibitor A51 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A51 induces leukemia cell apoptosis, and has potent anti-leukemic activities. Casein Kinase inhibitor A51 Chemical Structure
  68. GC63463 Casein Kinase inhibitor A86 Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities. Casein Kinase inhibitor A86 Chemical Structure
  69. GC43175 CAY10574 CAY10574 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAY10574 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity. CAY10574 Chemical Structure
  70. GC40515 CAY10577 Casein kinase 2 (CK2) is a serine/threonine-selective protein kinase involved in many signal transduction pathways. CAY10577 Chemical Structure
  71. GC43177 CAY10578 Casein Kinase 2 (CK2) is a constitutive protein kinase involved in many signal transduction pathways. CAY10578 Chemical Structure
  72. GC12971 CAY10603

    HDAC 6 inhibitor, Histone Deacetylase Inhibitor VIII

    potent and selective inhibitor of HDAC6

     CAY10603 Chemical Structure
  73. GC46113 CAY10744 A topoisomerase II-α poison CAY10744 Chemical Structure
  74. GC47059 CAY10760 An inhibitor of the RAD51-BRCA2 interaction CAY10760 Chemical Structure
  75. GC52006 CB-096 An inhibitor of RAN translation CB-096 Chemical Structure
  76. GC43209 CB-1954

    NSC 115829, Tretazicar

     CB-1954 (CB 1954), an antitumor prodrug, is highly selective against the Walker 256 rat tumour line. CB-1954 is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. CB-1954 in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1). CB-1954 Chemical Structure
  77. GC73843 CB07-Exatecan CB07-Exatecan is an ADC drug-Linker conjugate that can be used for the synthesis of ADCs. CB07-Exatecan Chemical Structure
  78. GC14058 CBHA

    Histone Deacetylase Inhibitor II,m-Carboxycinnamic Acid bis-Hydroxamide

     CBHA is a potent HDAC inhibitor, exhibiting ID50 values of 10 and 70 nM in vitro for HDAC1 and HDAC3, respectively. CBHA also induces apoptosis and suppresses tumor growth. CBHA Chemical Structure
  79. GC16654 CC-115 mTOR/DNA-PK inhibitor CC-115 Chemical Structure
  80. GC34121 CC-115 hydrochloride CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling. CC-115 hydrochloride Chemical Structure
  81. GC19089 CC-671 CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 uM for TTK and CLK2, respectively. CC-671 Chemical Structure
  82. GC50085 CCT 241533 dihydrochloride Potent Chk2 inhibitor CCT 241533 dihydrochloride Chemical Structure
  83. GC32741 CCT-251921 CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM. CCT-251921 Chemical Structure
  84. GC18053 CCT241533 A selective Chk2 inhibitor CCT241533 Chemical Structure
  85. GC17105 CCT241533 hydrochloride A selective Chk2 inhibitor CCT241533 hydrochloride Chemical Structure
  86. GC14772 CCT244747 Potent and selective CHK1 inhibitor CCT244747 Chemical Structure
  87. GC19093 CCT245737 CCT245737 is a orally active and seletive Chk1 inhibitor, with an IC50 of 1.3 nM. CCT245737 Chemical Structure
  88. GC35628 Cdc7-IN-1 Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of Cdc7 kinase, with an IC50 value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death. Cdc7-IN-1 Chemical Structure
  89. GC62427 Cdc7-IN-5 Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle. Cdc7-IN-5 Chemical Structure
  90. GC73970 CDDD11-8 CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 Chemical Structure
  91. GC12425 CDK inhibitor II

    CDK inhibitorII

     CDK inhibitor II Chemical Structure
  92. GC38899 CDK ligand for PROTAC hydrochloride CDK ligand for PROTAC hydrochloride Chemical Structure
  93. GC62168 CDK-IN-6 CDK-IN-6, a class of pyrazolo[1,5-a]pyrimidine compound, is a CDK inhibitor with anticancer activities. CDK-IN-6 Chemical Structure
  94. GC68846 CDK1-IN-2

    CDK1-IN-2 is a CDK1 inhibitor (IC50: 5.8 μM).

     CDK1-IN-2 Chemical Structure
  95. GC63499 CDK12-IN-2

    CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM) with good physicochemical properties.

     CDK12-IN-2 Chemical Structure
  96. GC68845 CDK12-IN-5

    CDK12-IN-5 is a pyrazole-triazine compound that is an effective inhibitor of CDK12, with an IC50 of 23.9 nM at high ATP (2 mM). CDK12-IN-5 has no effect on CDK2/Cyclin E (IC50=173 μM) and CDK9/Cyclin T1 (IC50=127 μM) at high ATP (2 mM) (WO2021116178A1).

     CDK12-IN-5 Chemical Structure
  97. GC68847 CDK2-IN-13

    CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC50 value of 12 μM. CDK2-IN-13 can be used for cancer research.

     CDK2-IN-13 Chemical Structure
  98. GC73976 CDK2-IN-23 CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC50 = 0.29 nM). CDK2-IN-23 Chemical Structure
  99. GC35632 CDK2-IN-4 CDK2-IN-4 is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM). CDK2-IN-4 Chemical Structure
  100. GC65190 CDK4/6-IN-11 CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader. CDK4/6-IN-11 Chemical Structure
  101. GC68848 CDK4/6-IN-15

    CDK4/6-IN-15 is an orally effective and selective CDK4/6 inhibitor. It can effectively inhibit cancer cell growth. CDK4/6-IN-15 blocks the cell cycle in the G1 phase and inhibits phosphorylation of retinoblastoma tumor suppressor protein (Rb) at S780 site and E2 factor (E2F)-regulated gene expression in retinoblastoma tumors.

     CDK4/6-IN-15 Chemical Structure

Items 401 to 500 of 1684 total

per page
  2. 3
  3. 4
  4. 5
  5. 6
  6. 7

Set Descending Direction